Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) was down 0.9% on Tuesday . The company traded as low as $53.81 and last traded at $53.94, with a volume of 143,064 shares changing hands. The stock had previously closed at $54.45.

A number of equities research analysts have weighed in on RDY shares. Zacks Investment Research downgraded shares of Dr. Reddy’s Laboratories from a “hold” rating to a “sell” rating in a report on Wednesday, May 4th. Goldman Sachs Group Inc. started coverage on shares of Dr. Reddy’s Laboratories in a report on Monday, May 2nd. They issued a “neutral” rating for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. Dr. Reddy’s Laboratories presently has an average rating of “Hold” and an average price target of $61.00.

The company’s 50 day moving average price is $48.29 and its 200-day moving average price is $45.77. The stock has a market capitalization of $9.14 billion and a P/E ratio of 30.95.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings data on Thursday, May 12th. The company reported $0.07 earnings per share (EPS) for the quarter. The company had revenue of $567 billion for the quarter, compared to the consensus estimate of $2.41 billion. On average, equities research analysts predict that Dr. Reddy’s Laboratories Ltd. will post $2.05 EPS for the current fiscal year.

The business also recently disclosed an annual dividend, which will be paid on Monday, July 18th. Shareholders of record on Monday, July 18th will be issued a dividend of $0.277 per share. The ex-dividend date is Thursday, July 14th.

Other hedge funds have made changes to their positions in the company. Principal Financial Group Inc. raised its stake in shares of Dr. Reddy’s Laboratories by 99.8% in the fourth quarter. Principal Financial Group Inc. now owns 492,288 shares of the company’s stock worth $22,788,000 after buying an additional 245,913 shares during the period. Morgan Stanley raised its stake in shares of Dr. Reddy’s Laboratories by 366.0% in the fourth quarter. Morgan Stanley now owns 308,997 shares of the company’s stock worth $14,303,000 after buying an additional 242,689 shares during the period. GAM Holding AG raised its stake in shares of Dr. Reddy’s Laboratories by 157.7% in the fourth quarter. GAM Holding AG now owns 123,200 shares of the company’s stock worth $5,703,000 after buying an additional 75,400 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Dr. Reddy’s Laboratories by 5.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 655,355 shares of the company’s stock worth $30,336,000 after buying an additional 31,714 shares during the period. Finally, Russell Frank Co raised its stake in shares of Dr. Reddy’s Laboratories by 8.6% in the fourth quarter. Russell Frank Co now owns 161,832 shares of the company’s stock worth $7,492,000 after buying an additional 12,758 shares during the period.

Dr. Reddy’s Laboratories Limited is an integrated global pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Global Generics segment consists of its business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.